Table 1.

Baseline characteristics of AASK cohort by serum alkaline phosphatase groups

Baseline CharacteristicAlkaline Phosphatase <80 (mean 63 ± 10) IU/L (n = 527)Alkaline Phosphatase ≥80 (mean 106 ± 37) IU/L (n = 567)P Valuea
Demographics and trial characteristics
    age (yr)54.0 ± 10.854.9 ± 10.60.18
    male gender (%)342 (65)327 (58)0.02
Randomized drug group
    ramipril (%)201 (38)235 (41)0.27
    metoprolol (%)214 (41)227 (40)0.85
    amlodipine (%)112 (21)105 (19)0.29
Randomized BP group
    strict control (%)253 (48)287 (51)0.40
    usual control (%)274 (52)280 (49)0.40
Clinical characteristics
    atherosclerotic conditions (%)73 (14)82 (14)0.80
    congestive heart failure (%)12 (2)16 (3)0.70
    current or past smoking (%)290 (55)343 (60)0.08
    BMI (kg/m2)30.7 ± 6.430.4 ± 6.80.50
    MAP (mmHg)114.5 ± 16.0113.6 ± 16.10.36
    GFR (ml/min/1.73 m2)47.8 ± 13.445.1 ± 13.70.001
Laboratory data
    serum AST (IU/L)23.0 ± 13.123.3 ± 12.10.71
    serum LDH (IU/L)177.7 ± 41.4179.8 ± 44.20.41
    serum total bilirubin (mg/dl)0.5 ± 0.20.5 ± 0.30.09
    serum GGT (IU/L)38.5 ± 64.354.8 ± 70.5<0.001
    serum albumin (g/dl)4.3 ± 0.34.3 ± 0.40.88
    urine protein-to-creatinine ratiob (mg/g)70 (30 – 310)90 (30 – 410)0.03
    serum calcium (mg/dl)9.2 ± 0.59.2 ± 0.50.75
    serum phosphorus (mg/dl)3.5 ± 0.73.5 ± 0.70.89
    serum calcium phosphorus product (mg/dl)b32.2 ± 7.032.3 ± 6.30.95
  • a P values calculated by ANOVA for continuous variables and Fisher's exact tests for categorical variables.

  • b Geometric mean (interquartile range) presented.